echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > 39 drugs will increase in price

    39 drugs will increase in price

    • Last Update: 2021-07-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    01 A batch of drugs increased in price

    01 A batch of drugs increased in price

    Recently, the Gansu Provincial Public Resources Trading Center issued the "Notice on Announcement of the Market Approval Results of the 2020 Drug Centralized Procurement Dynamic Adjustments to Proposed Price Increases
    .
    "

    According to the notice, there are 2031 drugs to be increased in the dynamic adjustment of centralized drug procurement in 2020, of which 39 meet the price adjustment conditions, 358 have applied for an extension of the market approval window, and 7 enterprises will be adjusted after the establishment of an enterprise complaint and will be adjusted after expert evaluation.
    1,626 applications for abandoning price adjustments or not applying for price adjustments were deemed as abandoning price adjustments (see the end of the article for details)

    .

    The results of the adjustment will be implemented on August 10, 2021.
    Drugs that meet the price adjustment conditions will be adjusted on the platform and prices from the date of implementation.
    Medical institutions across the province will purchase at the new price, and the Sunshine platform bargaining price shall not be higher than the dynamic adjustment quotation of the enterprise

    .

    If the enterprise applies for abandoning the price adjustment or does not apply for the drugs deemed as abandoning the price adjustment, the price will be executed in accordance with the original bid-winning price
    .

    Drugs that apply for an extension of the market approval window will continue to retain their qualifications for market approval, and the platform and bid-winning prices will not be updated, and the purchase volume at the new declared price shall reach 90% of the total purchase volume of the previous year (not less than 5 companies).
    Procurement by medical institutions above the national level), price adjustments can be made after expert argumentation

    .

    For drugs that were not purchased in the previous year, the purchase amount at the new declared price reaches 90% of the total purchase amount this year (not less than 5 second-level or higher medical institutions purchase), and price adjustments can be made after expert argumentation
    .

    02 Price adjustment window

    02 Price adjustment window

    Controlling drug prices is the core of medical reform.
    In recent years, the direction of drug adjustments has also focused on price reductions.
    There are also certain restrictions on drug price increases this time

    .

    According to the documents, the bid-winning drug company must meet the following conditions to apply for an increase in the winning bid price or the online reference price:

    (1) It must be a drug in the dynamic adjustment catalog of the current year
    .

    (2) The application price shall not be higher than the national minimum bid-winning online price for the drug being implemented.
    If the online price is the enterprise's self-quotation, it shall be declared at the lowest actual transaction price in the province

    .

    (3) The application price sets a three-month market approval window period, and the platform publicity and variety dynamic adjustments are carried out first
    .

    It can be seen that according to the price increase regulations of Gansu Province, there are more restrictions and the price increase is limited.
    The state is more of a window for drug companies to adjust prices

    .

    The document shows that the implementation of this policy is to ensure the quality and supply of medicines
    .
    Too high prices of medicines are not good, but too low prices can also affect the supply of medicines

    .

    On November 7, 2018, the Liaoning Pharmaceutical Collection Center issued the 2018 Early Warning Forecast for Shortage Drugs No.
    3, stating that 54 drugs could not be supplied and distributed normally.
    After the investigation, 15 pharmaceutical companies still reported that they were affected by raw materials and the transformation of their production lines.
    This resulted in insufficient production capacity; 6 pharmaceutical companies reported that they had stopped production because they could not purchase raw materials; 2 drugs could not be supplied normally due to rising prices of raw materials and low bid-winning prices

    .

    Regarding this matter, the general opinion in the industry is that the price increase of raw materials and the low bid price of the medicine are the reasons why the supply cannot be guaranteed
    .

    03 Strengthen monitoring

    03 Strengthen monitoring

    In order to ensure the supply of medicines, the state has successively introduced a number of policies
    .

    Documents such as the "Opinions of the General Office of the State Council on Further Doing a Good Job in Guaranteeing Supply and Stabilization of Drugs in Shortage" and the "Opinions of the National Medical Security Administration on Doing a Good Job in Current Drug Price Management" all mention strengthening the testing of drug prices and the process of drug use.
    Management

    .
    Resolutely deal with the abnormal increase in the price of raw materials, and promptly respond to the shortage of medicines

    .

    Recently, the National Medical Insurance Administration issued the "Notice on Carrying out Monitoring of Abnormal Changes in Drug Prices and Supply
    .
    " In the notice, the National Medical Insurance Bureau stated that it has decided to rely on the provincial centralized drug procurement platform to trial the monitoring of abnormal changes in drug prices and supply

    .
    In accordance with the requirements of the National Medical Insurance Administration, the provincial-level centralized drug procurement platform will include all drugs traded on the Internet into the scope of routine monitoring, and will focus on monitoring some drugs that have a concentrated clinical response

    .

    In the notice, the National Medical Insurance Administration also delineated a “list of drugs for key monitoring of abnormal price and supply fluctuations” involving 142 varieties, involving arubicin injection, cytarabine injection, atropine injection, aminophylline Tablets and other common drugs that are prone to clinical shortages
    .

    Medicine is a special commodity, and its price needs to be subject to certain restrictions.
    However, in the market, it is affected by the rising cost of raw materials, the rising cost of materials such as auxiliary materials and packaging materials, and the improvement of technical quality standards, which will actually lead to an increase in production costs

    .
    How to find a balance between restricting prices and ensuring supply requires constant exploration

    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.